Inovio to test prime and boost vaccine strategy with ChronTech and Transgene

[Guest guest]

http://www.proactiveinvestors.com/companies/news/13916/inovio-to-test-prime-and-\

boost-vaccine-strategy-with-chrontech-and-transgene-13916.html

Inovio to test " prime and boost " vaccine strategy with ChronTech and Transgene

Mon 10:40 am by Deborah Sterescu

Inovio Pharmaceuticals (AMEX:INO) said Monday it has signed a deal with French

biopharm company Transgene (EPA:TNG) and Swedish vaccine developer ChronTech

Pharma to test a vaccination strategy that involves a repeat " boost " approach.

The strategy, which consists of an initial prime vaccine followed by a boost of

the same vaccine, will be tested in a phase one clinical trial for a therapeutic

hepatitis C vaccine candidate.

The companies will use different prime and boost vaccines with the goal of

obtaining a clinical effect by inducing different immune responses, they said.

The phase one study, to be started later this year, will use ChronTech's plasmid

DNA vaccine delivered by Inovio's in vivo electroportation device as the prime,

followed by Transgene's TG4040 vaccine as the boost.

" We are pleased to participate in this collaboration to develop a potentially

more potent HCV [hepatitis C virus] vaccine combination approach and to

contribute Inovio's electroporation delivery technology and its well-validated

ability to transform the potency of DNA vaccines, " said Inovio president and CEO

Dr. J ph Kim.

Chronic hepatitis C, with a disease prevalence exceeding 170 million worldwide,

is notoriously difficult to treat as current therapies have serious side

effects. The infectious disease affects the liver, and can lead to liver

failure or cancer.

ChronTech's DNA vaccine was already tested using Inovio's delivery device, and

was reported to be safe, generating antigen-specific immune responses. In a

phase one study, 83% of participants who were monitored for an extended period

of time were free of the virus six months after they completed standard-of-care

treatment.

DNA vaccines are designed to generate broader, cross-protective immune responses

across different virus strains, unlike existing vaccines that must be matched to

a specific serotype. When used to deliver DNA vaccines, Inovio's

electroportation systems can increase levels of immune responses by 100 times or

more compared to DNA delivered without other delivery enhancements.

In preclinical studies, the three companies also said that the " prime and boost "

approach showed greater immune responses than those seen with vaccines injected

separately.

Under the collaboration agreement, the companies will share the study costs. The

new phase one trial will enroll 12 patients with chronic hepatitis C at a site

in Germany.

[Guest guest]

http://www.proactiveinvestors.com/companies/news/13916/inovio-to-test-prime-and-\

boost-vaccine-strategy-with-chrontech-and-transgene-13916.html

Inovio to test " prime and boost " vaccine strategy with ChronTech and Transgene

Mon 10:40 am by Deborah Sterescu

Inovio Pharmaceuticals (AMEX:INO) said Monday it has signed a deal with French

biopharm company Transgene (EPA:TNG) and Swedish vaccine developer ChronTech

Pharma to test a vaccination strategy that involves a repeat " boost " approach.

The strategy, which consists of an initial prime vaccine followed by a boost of

the same vaccine, will be tested in a phase one clinical trial for a therapeutic

hepatitis C vaccine candidate.

The companies will use different prime and boost vaccines with the goal of

obtaining a clinical effect by inducing different immune responses, they said.

The phase one study, to be started later this year, will use ChronTech's plasmid

DNA vaccine delivered by Inovio's in vivo electroportation device as the prime,

followed by Transgene's TG4040 vaccine as the boost.

" We are pleased to participate in this collaboration to develop a potentially

more potent HCV [hepatitis C virus] vaccine combination approach and to

contribute Inovio's electroporation delivery technology and its well-validated

ability to transform the potency of DNA vaccines, " said Inovio president and CEO

Dr. J ph Kim.

Chronic hepatitis C, with a disease prevalence exceeding 170 million worldwide,

is notoriously difficult to treat as current therapies have serious side

effects. The infectious disease affects the liver, and can lead to liver

failure or cancer.

ChronTech's DNA vaccine was already tested using Inovio's delivery device, and

was reported to be safe, generating antigen-specific immune responses. In a

phase one study, 83% of participants who were monitored for an extended period

of time were free of the virus six months after they completed standard-of-care

treatment.

DNA vaccines are designed to generate broader, cross-protective immune responses

across different virus strains, unlike existing vaccines that must be matched to

a specific serotype. When used to deliver DNA vaccines, Inovio's

electroportation systems can increase levels of immune responses by 100 times or

more compared to DNA delivered without other delivery enhancements.

In preclinical studies, the three companies also said that the " prime and boost "

approach showed greater immune responses than those seen with vaccines injected

separately.

Under the collaboration agreement, the companies will share the study costs. The

new phase one trial will enroll 12 patients with chronic hepatitis C at a site

in Germany.

[Guest guest]

http://www.proactiveinvestors.com/companies/news/13916/inovio-to-test-prime-and-\

boost-vaccine-strategy-with-chrontech-and-transgene-13916.html

Inovio to test " prime and boost " vaccine strategy with ChronTech and Transgene

Mon 10:40 am by Deborah Sterescu

Inovio Pharmaceuticals (AMEX:INO) said Monday it has signed a deal with French

biopharm company Transgene (EPA:TNG) and Swedish vaccine developer ChronTech

Pharma to test a vaccination strategy that involves a repeat " boost " approach.

The strategy, which consists of an initial prime vaccine followed by a boost of

the same vaccine, will be tested in a phase one clinical trial for a therapeutic

hepatitis C vaccine candidate.

The companies will use different prime and boost vaccines with the goal of

obtaining a clinical effect by inducing different immune responses, they said.

The phase one study, to be started later this year, will use ChronTech's plasmid

DNA vaccine delivered by Inovio's in vivo electroportation device as the prime,

followed by Transgene's TG4040 vaccine as the boost.

" We are pleased to participate in this collaboration to develop a potentially

more potent HCV [hepatitis C virus] vaccine combination approach and to

contribute Inovio's electroporation delivery technology and its well-validated

ability to transform the potency of DNA vaccines, " said Inovio president and CEO

Dr. J ph Kim.

Chronic hepatitis C, with a disease prevalence exceeding 170 million worldwide,

is notoriously difficult to treat as current therapies have serious side

effects. The infectious disease affects the liver, and can lead to liver

failure or cancer.

ChronTech's DNA vaccine was already tested using Inovio's delivery device, and

was reported to be safe, generating antigen-specific immune responses. In a

phase one study, 83% of participants who were monitored for an extended period

of time were free of the virus six months after they completed standard-of-care

treatment.

DNA vaccines are designed to generate broader, cross-protective immune responses

across different virus strains, unlike existing vaccines that must be matched to

a specific serotype. When used to deliver DNA vaccines, Inovio's

electroportation systems can increase levels of immune responses by 100 times or

more compared to DNA delivered without other delivery enhancements.

In preclinical studies, the three companies also said that the " prime and boost "

approach showed greater immune responses than those seen with vaccines injected

separately.

Under the collaboration agreement, the companies will share the study costs. The

new phase one trial will enroll 12 patients with chronic hepatitis C at a site

in Germany.

[Guest guest]

http://www.proactiveinvestors.com/companies/news/13916/inovio-to-test-prime-and-\

boost-vaccine-strategy-with-chrontech-and-transgene-13916.html

Inovio to test " prime and boost " vaccine strategy with ChronTech and Transgene

Mon 10:40 am by Deborah Sterescu

Inovio Pharmaceuticals (AMEX:INO) said Monday it has signed a deal with French

biopharm company Transgene (EPA:TNG) and Swedish vaccine developer ChronTech

Pharma to test a vaccination strategy that involves a repeat " boost " approach.

The strategy, which consists of an initial prime vaccine followed by a boost of

the same vaccine, will be tested in a phase one clinical trial for a therapeutic

hepatitis C vaccine candidate.

The companies will use different prime and boost vaccines with the goal of

obtaining a clinical effect by inducing different immune responses, they said.

The phase one study, to be started later this year, will use ChronTech's plasmid

DNA vaccine delivered by Inovio's in vivo electroportation device as the prime,

followed by Transgene's TG4040 vaccine as the boost.

" We are pleased to participate in this collaboration to develop a potentially

more potent HCV [hepatitis C virus] vaccine combination approach and to

contribute Inovio's electroporation delivery technology and its well-validated

ability to transform the potency of DNA vaccines, " said Inovio president and CEO

Dr. J ph Kim.

Chronic hepatitis C, with a disease prevalence exceeding 170 million worldwide,

is notoriously difficult to treat as current therapies have serious side

effects. The infectious disease affects the liver, and can lead to liver

failure or cancer.

ChronTech's DNA vaccine was already tested using Inovio's delivery device, and

was reported to be safe, generating antigen-specific immune responses. In a

phase one study, 83% of participants who were monitored for an extended period

of time were free of the virus six months after they completed standard-of-care

treatment.

DNA vaccines are designed to generate broader, cross-protective immune responses

across different virus strains, unlike existing vaccines that must be matched to

a specific serotype. When used to deliver DNA vaccines, Inovio's

electroportation systems can increase levels of immune responses by 100 times or

more compared to DNA delivered without other delivery enhancements.

In preclinical studies, the three companies also said that the " prime and boost "

approach showed greater immune responses than those seen with vaccines injected

separately.

Under the collaboration agreement, the companies will share the study costs. The

new phase one trial will enroll 12 patients with chronic hepatitis C at a site

in Germany.